Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

C. Gaudy-Marqueste

h-index 32 View on Semantic Scholar

We have 2 of 179 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Oct 2026

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

PURPOSE Tovorafenib is an oral, selective, CNS-penetrant, type II inhibitor of BRAF and CRAF. BRAF fusions and CRAF/RAF1 fusions and amplifications are rare oncogenic drivers in many solid tumors. The phase II DAY101-102a substudy of FIRELIGHT-1 (ClinicalTrials.gov identifier: NCT04985604) investigated the efficacy and...

M. Vieito, E. Cabanas, I. Mehmi et al. · 0 citations
Aug 2026

MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.

It is demonstrated that activation of β-catenin is associated with a poor prognosis in melanoma and inhibiting the enzymatic activity of MICAL2 offers a promising and innovative strategy to improve outcomes in β-catenin-driven melanoma.

P. Sohier, J. Raymond, Zackie Aktary et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.